Copertina

P‐tau217 testing impact on intended management of patients presenting with cognitive impairment: A randomized clinical utility study

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Samantha C. Burnham, Haoyan Hu, Yifeng Tang, Anthony Sireci, Michael J. Pontecorvo, Paul E. Schulz, Rosemary D. Laird, Curtis P. Schreiber, Rose C. Beck
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Clinical validation of the Lilly SP‐X P‐tau217 assay: Performance in underrepresented cohorts
di: Michael E. Hodsdon, et al.
Pubblicazione: (2025)

Associations of plasma phosphorylated tau217 with cognitive impairment and brain microstructural alterations in Alzheimer's disease
di: Miguel Ángel Rivas‐Fernández, et al.
Pubblicazione: (2026)

Diagnostic utility of plasma p‐tau217 differs by Alzheimer's disease tau‐based subtypes
di: Seyed Hani Hojjati, et al.
Pubblicazione: (2025)

Clinical performance of the fully automated Lumipulse plasma p‐tau217 assay in mild cognitive impairment and mild dementia
di: Adam H. Dyer, et al.
Pubblicazione: (2025)

Plasma p‐tau217 and cognitive impairment: Evaluating biomarker equity across racial/ethnic groups in HABS‐HD
di: Cellas A. Hayes, et al.
Pubblicazione: (2026)

Performance of plasma p‐tau217 and NfL in an unselected memory clinic setting
di: Rebecca Z. Rousset, et al.
Pubblicazione: (2024)

Plasma p‐tau217 for Alzheimer's disease diagnosis: a memory clinic implementation approach
di: Giorgia Brodini, et al.
Pubblicazione: (2026)

Classifying mild cognitive impairment from normal cognition: fMRI complexity matches tau PET performance
di: Kay Jann, et al.
Pubblicazione: (2025)

Plasma p‐tau217 and APOE genotype: Prodromal Alzheimer's disease staging
di: Ann M. Stowe, et al.
Pubblicazione: (2026)

Preclinical dementia rating scores are associated with plasma phosphorylated tau‐217
di: Qi Huang, et al.
Pubblicazione: (2025)

Clinical decision points for two plasma p‐tau217 laboratory developed tests in neuropathology confirmed samples
di: Anna E. Mammel, et al.
Pubblicazione: (2025)

Identifying cognitive test scores associated with early tau burden in Alzheimer's disease
di: Caitlin M. Terao, et al.
Pubblicazione: (2025)

The impact of mild cognitive impairment on healthcare utilization and costs: A UK Biobank study
di: Craig Ritchie, et al.
Pubblicazione: (2025)

Impact of the Lilly SP‐X p ‐tau217 plasma assay on management of patients with cognitive impairment: results of a clinical utility study in an ethnically and racially representative cohort, Lilly J4Y‐MC‐B002
di: Samantha C. Burnham, et al.
Pubblicazione: (2025)

Cross‐sectional study of plasma phosphorylated tau 217 in persons without dementia
di: Toni T. Saari, et al.
Pubblicazione: (2025)

Associations of plasma p‐Tau217 with cognitive domain performance in clinically unimpaired participants: Evidence from HABS‐HD
di: Zara Najmi, et al.
Pubblicazione: (2026)

Clinical performance of scalable automated p‐tau 217 multi‐analyte algorithmic blood test with reduced intermediate zone using multiplexed digital immunoassay
di: David H. Wilson, et al.
Pubblicazione: (2025)

Interchangeability of CSF and PET to identify Alzheimer's disease pathology
di: Samantha C. Burnham, et al.
Pubblicazione: (2026)

Comparison of three plasma p‐tau217 assays to detect PET‐confirmed Alzheimer's pathologies
di: Sayo Matsuura, et al.
Pubblicazione: (2026)

Excessive sleep is associated with worse cognition, cognitive decline, and dementia in mild cognitive impairment
di: Marieclaire Overton, et al.
Pubblicazione: (2025)

Artificial intelligence detection of cognitive impairment in older adults during walking
di: Shuichi P. Obuchi, et al.
Pubblicazione: (2024)

Midlife sensory and motor functions improve long‐term predictions of cognitive decline and incidence of cognitive impairment
di: Carla R. Schubert, et al.
Pubblicazione: (2024)

Clinical and neuropathological associations of plasma Aβ42/Aβ40, p‐tau217 and neurofilament light in sporadic frontotemporal dementia spectrum disorders
di: Binita Rajbanshi, et al.
Pubblicazione: (2025)

Real‐world use of diagnostic tests for mild cognitive impairment, Alzheimer's disease, and other dementias in Medicare fee‐for‐service beneficiaries
di: Jessie T. Yan, et al.
Pubblicazione: (2025)

Longitudinal changes in the brain‐age gap in mild cognitive impairment and their relationships with neuropsychological functions and Alzheimer's disease biomarkers
di: Rachel R. Jin, et al.
Pubblicazione: (2025)

Hallucinations and delusions are associated with elevated tau PET signal independent of age, clinical severity, and amyloid burden
di: Aubrey S Johnson, et al.
Pubblicazione: (2026)

Diagnosing Alzheimer's disease: Which dementia screening test to use in elderly Puerto Ricans with mild cognitive impairment and early Alzheimer's disease?
di: María A. Rodríguez‐Santiago, et al.
Pubblicazione: (2024)

Fixel‐based analysis and free‐water metrics in subjective cognitive decline and cognitive impairment no dementia
di: Zheng Long Lee, et al.
Pubblicazione: (2026)

Clinical classification of memory and cognitive impairment with multimodal digital biomarkers
di: Russell Banks, et al.
Pubblicazione: (2024)

Clinical and demographic factors modify the association between plasma phosphorylated tau‐181 and cognition
di: Corey J. Bolton, et al.
Pubblicazione: (2024)

Survey among experts on the future role of tau‐PET in clinical practice and trials
di: Marie R. Vermeiren, et al.
Pubblicazione: (2024)

Task‐evoked pupillary responses as potential biomarkers of mild cognitive impairment
di: Julius Opwonya, et al.
Pubblicazione: (2024)

Prevalence and predictors of diagnosed mild cognitive impairment among Medicare beneficiaries
di: Elyse Couch, et al.
Pubblicazione: (2025)

Modeling contributions of cognition and apathy to functional impairment in younger‐onset dementia
di: Samuel L. Warren, et al.
Pubblicazione: (2026)

The prognosis of mild cognitive impairment: A systematic review and meta‐analysis
di: Simone Salemme, et al.
Pubblicazione: (2025)

Non‐Alzheimer's amnestic mild cognitive impairment with medial temporal hypometabolism
di: Sebastiaan De Keersmaecker, et al.
Pubblicazione: (2024)

The Rapid Naming Test: Neuroanatomical validity and clinical utility
di: Kelly J. Atkins, et al.
Pubblicazione: (2025)

Digital cognition plus plasma p‐Tau217 and Aβ42/40 powerfully predict Alzheimer's progression
di: Ahmet Begde, et al.
Pubblicazione: (2026)

Validation of regression‐based change formulae for mild cognitive impairment and Alzheimer's disease
di: Kevin Duff, et al.
Pubblicazione: (2024)

Correction to “The prognosis of mild cognitive impairment: A systematic review and meta‐analysis”
Pubblicazione: (2025)